Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report) shot up 3.4% during trading on Wednesday . The company traded as high as $1.53 and last traded at $1.53. 595,311 shares changed hands during trading, an increase of 2% from the average session volume of 585,289 shares. The stock had previously closed at $1.48.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen downgraded shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, May 12th.
Check Out Our Latest Research Report on PLX
Protalix BioTherapeutics Trading Down 3.7%
The company has a market capitalization of $113.44 million, a PE ratio of -10.96 and a beta of -0.23. The stock's fifty day moving average is $1.71 and its two-hundred day moving average is $2.16.
Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. As a group, analysts anticipate that Protalix BioTherapeutics, Inc. will post 0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Protalix BioTherapeutics
A number of large investors have recently made changes to their positions in the company. Northern Trust Corp lifted its holdings in shares of Protalix BioTherapeutics by 1,299.4% in the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company's stock worth $1,376,000 after buying an additional 679,451 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Protalix BioTherapeutics during the first quarter worth approximately $1,236,000. Goldman Sachs Group Inc. increased its stake in Protalix BioTherapeutics by 482.3% during the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company's stock worth $741,000 after acquiring an additional 239,751 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Protalix BioTherapeutics by 159.0% in the first quarter. Jane Street Group LLC now owns 294,318 shares of the company's stock valued at $753,000 after buying an additional 180,702 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in Protalix BioTherapeutics during the 1st quarter worth $459,000. 16.53% of the stock is currently owned by institutional investors.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Further Reading
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
